Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025

Supplementary Figure S6 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Observational analysis shows reduced Tregs via myeloid Trem2-knockout in NASH models, indicating potential for improved checkpoint immunotherapy.

Key Points

  • Reduced Tregs were associated with myeloid Trem2-knockout, providing a pathway for enhancing checkpoint immunotherapy.
  • Inhibition of NETs formation was a key metric observed in the study, linking it to the reduction of immunosuppressive factors.
  • Analysis indicated that targeting myeloid Trem2 could reprogram the tumor microenvironment in hepatocarcinogenesis.
  • These findings suggest that Trem2-targeting may be a potential strategy in treating NASH-related liver cancer.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21ae4https://doi.org/10.1158/2326-6066.30255478
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S4 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  2. 2Supplementary Figure S5 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  3. 3Supplementary Figure S7 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  4. 4Supplementary Figure S1 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  5. 5Supplementary Figure S3 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025